Clinical Characteristics and Treatment Strategies for Group B Streptococcus (GBS) Infection in Pediatrics: A Systematic Review
Rattachement africain : sa. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background and Objectives: Group B streptococcus (GBS) is the leading cause of infections in neonates with high fatality rates. GBS is caused by the streptococcus bacterium known as streptococcus agalactiae, which is highly contagious and can be transmitted from pregnant women to infants. GBS infection can occur as an early onset or late-onset infection and has different treatment strategies. Antibiotics are effective in treating GBS infections at early stages. The aim of this systematic review was to summarize the clinical characteristics and treatment strategies for GBS, with a focus on antibiotics. Material and Methods: The findings of this review were reported in accordance with the PRISMA 2020 guidelines and a flow diagram of the study selection process, a summary of the included studies, a description of the study characteristics, a summary of the results, a discussion of the implications of the findings, and a conclusion are included. Overall, the authors followed a rigorous methodology to ensure that this review is comprehensive and inclusive of relevant studies on GBS infection and its treatment. Results: Overall, 940 studies were reviewed and only the most relevant 22 studies were included in the systematic review. This review describes the characteristics of patients in different studies related to early onset GBS disease and presents various treatment strategies and outcomes for GBS infection in pediatrics. The studies suggest that preventive measures, risk-based intrapartum antibiotic prophylaxis, and maternal vaccination can significantly reduce the burden of GBS disease, but late-onset GBS disease remains a concern, and more strategies are required to decrease its rate. Improvement is needed in the management of the risk factors of GBS. A conjugate vaccine with a serotype (Ia, Ib, II, III, and V) has been proven effective in the prevention of GBS in neonates. Moreover, penicillin is an important core antibiotic for treating early onset GBS (EOD). Conclusions: This systematic review summarizes the treatment comparison for GBS infections in neonates, with a primary focus on antibiotics. IAP (intrapartum antibiotic prophylaxis) according to guidelines, antenatal screening, and the development of a conjugate vaccine may be effective and could lower the incidence of the disease.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Clinical Characteristics and Treatment Strategies for Group B Streptococcus (GBS) Infection in Pediatrics: A Systematic Review
- Date Crossref
- 09/07/2023
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Northern Border University Department of Clinical Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Shaqra University Department of Clinical Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
King Faisal Specialist Hospital & Research Centre Department of Pharmaceutical Care pays non établi dans la noticeÉtablissement de santé
-
King Khaled Hospital pays non établi dans la noticeÉtablissement de santé
-
King Faisal University pays non établi dans la noticeUniversité ou école supérieure
-
University of Tabuk pays non établi dans la noticeUniversité ou école supérieure
-
Alrazi Medical Company pays non établi dans la noticeEntreprise
-
Department of Clinical Pharmacy pays non établi dans la noticeÉtablissement de santé
-
Hokmaa Taif Medical Complex pays non établi dans la noticeInstitution
-
College of Clinical Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Department of Pharmaceutical Care pays non établi dans la noticeInstitution
Department of Clinical Pharmacy — Northern Border University, Department of Clinical Pharmacy — Shaqra University et Department of Pharmaceutical Care — King Faisal Specialist Hospital & Research Centre, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.